Patrick Hwu: Can We Improve Immunotherapy for Hard-To-Treat Pediatric Cancers Like Rhabdomyosarcoma?
Patrick Hwu, President and CEO of the Moffitt Cancer Center, shared a post on X about recent paper by Lisa Marie Reindl et al., published in Journal of ImmunoTherapy of Cancer.
“Can we improve immunotherapy for hard-to-treat pediatric cancers like rhabdomyosarcoma?
A new study in the Journal for ImmunoTherapy of Cancer explored combining EGFR-targeted CAR natural killer (NK) cells with radiotherapy to treat rhabdomyosarcoma, the most common soft tissue sarcoma in children.
Researchers in the Ullrich Lab and Goethe University engineered primary human NK cells with an EGFR-specific CAR and found they could effectively kill rhabdomyosarcoma cells — including chemotherapy-resistant and patient-derived cells — in preclinical models. The real breakthrough?
Radiotherapy enhanced NK cell tumor infiltration and further reduced tumor growth when combined with CAR NK cell therapy.
This combination approach may offer a promising new strategy for treating aggressive, EGFR-expressing solid tumors.”
Tilte: Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy
Authors: Lisa Marie Reindl, Lida Jalili, Tobias Bexte, Sabine Harenkamp, Sophia Thul, Stephanie Hehlgans, Alina Wallenwein, Florian Rothweiler, Jindrich Cinatl, Martin Michaelis, Halvard Bonig, Elise Gradhand, Meike Vogler, Franz Rödel, Winfried S Wels, Evelyn Ullrich
Read The Full Article at Journal of ImmunoTherapy of Cancer.
More posts featuring Patrick Hwu on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023